Schedule 13G ownership disclosure
Iovance Biotherapeutics Inc
Common Stock · CUSIP: 462260100
Event date: 2025-06-30
- Filing-level shares
- 25,076,472
- Percent of class
- 7.50%
- The Vanguard Group
Shares: 25,076,472 · Class: 7.50%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000932471-25-000911
- Form type
- SCHEDULE 13G/A
- Filer
- IOVANCE BIOTHERAPEUTICS, INC.
- CIK
- CIK 1425205
- Filed
- Jul 29, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership